Furthermore, synthetic androgen treatment downregulated SVIP levels but upregulated other ERAD components, including gp78, p97/VCP, and Derlin1, enhancing ERAD proteolytic activity both in glioma and prostate cancer cells [16,17]. Here, SVIP is linked to prostate carcinoma.